Show simple item record

dc.contributor.authorHeadrick, Johnen_US
dc.contributor.authorHsu, Annaen_US
dc.contributor.authorJ. Gross, Garretten_US
dc.contributor.authorPeart, Jasonen_US
dc.contributor.authorR. Gross, Ericen_US
dc.contributor.authorReichelt, Melissaen_US
dc.date.accessioned2017-04-04T17:03:21Z
dc.date.available2017-04-04T17:03:21Z
dc.date.issued2008en_US
dc.date.modified2011-11-03T06:15:09Z
dc.identifier.issn03008428en_US
dc.identifier.doi10.1007/s00395-008-0726-zen_AU
dc.identifier.urihttp://hdl.handle.net/10072/23382
dc.description.abstractThe temporal properties of kappa-opioid receptor (?-OR) mediated cardioprotection are less well characterised than delta-opioid receptor (d-OR) responses. This study was aimed at delineating the time course of ?-OR-mediated protection in two experimental models: an in vivo rat model of regional myocardial infarction (30 min of left coronary artery occlusion with 120 min of reperfusion), and an in vitro perfused murine heart model (undergoing 25 min of global ischemia and 45 min of reperfusion). In the rat model, the selective ?-OR agonist U50, 488 (0.1 mg/kg, IV bolus), administered either 10 min prior to ischemia or 5 min prior to reperfusion, significantly reduced infarct size (38 ᠳ% and 43 ᠲ% infarct size/area-at-risk (IS/AAR), respectively; P < 0.05) compared to untreated rats (56 ᠱ% IS/AAR). Administration of U50, 488 10 s after onset of reperfusion failed to elicit protection. Cardioprotection with U50,448 administered immediately prior to reperfusion was abolished by a ?-OR antagonist, (0.1 mg/kg nor-BNI), given 10 min prior to reperfusion. In the in vitro murine model, untreated hearts exhibited 28 ᠲ% (IS/AAR) infarct size. Infusion of U50, 488 (at a final 100 nM concentration) significantly limited infarct size in mouse hearts when applied at the onset of reperfusion (15 ᠲ% IS/AAR; P < 0.05), yet failed to afford protection when infused prior to ischemia. Additionally, in both models studied, treatment with either wortmannin or 5-hydroxydecanoate (5-HD) abrogated the protective effects of U50,488 applied just prior to reperfusion. In summary, ?-ORs afford cardioprotection primarily when activated prior to and not after reperfusion. This protection may involve activation of the PI3 kinase (PI3K) pathway and mitochondrial (mito) K ATP channels.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_AU
dc.languageEnglishen_US
dc.language.isoen_AU
dc.publisherDr. Dietrich Steinkopff Verlagen_US
dc.publisher.placeGermanyen_US
dc.relation.ispartofstudentpublicationNen_AU
dc.relation.ispartofpagefrom454en_US
dc.relation.ispartofpageto463en_US
dc.relation.ispartofissue5en_AU
dc.relation.ispartofjournalBasic Research in Cardiologyen_US
dc.relation.ispartofvolume103en_US
dc.rights.retentionYen_AU
dc.subject.fieldofresearchcode320503en_US
dc.subject.fieldofresearchcode329999en_US
dc.titleActivation of kappa-opioid receptors at reperfusion affords cardioprotection in both rat and mouse hearts.en_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.facultyGriffith Health, School of Medical Scienceen_US
gro.date.issued2008
gro.hasfulltextNo Full Text


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record